Clinical Trial Update: A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction [Phase 2]

View source ↗

Summary

A Phase 2 study of MLN0264 in gastric and gastroesophageal junction adenocarcinoma expressing GC-C was terminated. Results were posted in May 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• MLN0264

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Adenocarcinoma of the Stomach, Gastroesophageal Junction Expressing Guanylyl Cyclase C | Phase 2 | Status: TERMINATED | Results posted: 2017-05-15